Company / R&D Expense
BIO-PATH HOLDINGS, INC. R&D Expense History
FY2012-FY2018 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$4.6M
FY2018
5-year range
$1.6M / $5.5M
FY2014-FY2018
Trend
-16.0%
vs FY2017
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $5M to $5M over the past 2 years.
Based on SEC 10-K filings.
$5M in FY2018 with a 5-year CAGR of +24.8%.
Declined from $5M to $5M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +15.1%
- 5-Year CAGR
- +24.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +24.8%, indicating consistent growth.
- In FY2018, r&d expense decreased 16.0% year-over-year.
- Peak r&d expense was recorded in FY2017.
- Lowest r&d expense in the period was in FY2012.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -25.76 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2018 | $4.6M | -16.0% |
| FY2017 | $5.5M | +0.1% |
| FY2016 | $5.5M | +81.3% |
| FY2015 | $3.0M | +85.3% |
| FY2014 | $1.6M | +7.3% |
| FY2013 | $1.5M | +34.1% |
| FY2012 | $1.1M | - |
As of FY2018 · SEC 10-K · Updated Jun 29, 2026